CIK 0001590750 · Large accelerated filer
Viridian Therapeutics, Inc.\DE
Sign in to watch- Ticker
- VRDN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 471187261
- Phone
- 617.272.4600
- Business address
- 221 CRESCENT STREET, SUITE 103A, WALTHAM, MA, 02453
- Former names
- MIRAGEN THERAPEUTICS, INC., SIGNAL GENETICS, INC., SIGNAL GENETICS LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $348,194
- in 1 filing
Net −$348,194. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-04-01 | Violin Jonathan Chief Executive Officer | Sale | −26,400 | $18.92 | $499K | 544,505 |
| 2022-03-02 | Violin Jonathan Chief Executive Officer | Sale | −11,106 | $17.36 | $193K | 570,905 |
| 2022-03-01 | Violin Jonathan Chief Executive Officer | Sale | −18,894 | $17.82 | $337K | 582,011 |
| 2022-02-03 | Violin Jonathan Chief Executive Officer | Sale | −909 | $19.16 | $17K | 600,905 |
| 2022-02-02 | Humer Kristian CFO and CBO | Grant or award · Stock Option (Right to Buy) | +90,000 | 90,000 | ||
| 2022-02-02 | Katz Barrett Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +110,000 | 110,000 | ||
| 2022-02-02 | Meisner Lara General Counsel and Secretary | Grant or award · Stock Option (Right to Buy) | +90,000 | 90,000 | ||
| 2022-02-02 | Violin Jonathan Chief Executive Officer | Sale | −12,340 | $18.47 | $228K | 601,814 |
| 2022-02-02 | Violin Jonathan Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +280,000 | 280,000 | ||
| 2022-02-01 | Violin Jonathan Chief Executive Officer | Sale | −16,751 | $19.55 | $327K | 614,154 |
| 2021-12-31 | Humer Kristian CFO and CBO | Grant or award · Stock Option (Right to Buy) | +121,371 | 121,371 | ||
| 2021-12-08 | Violin Jonathan See Remarks | Conversion | +627,564 | 630,905 | ||
| 2021-12-08 | Violin Jonathan See Remarks | Conversion · Series A Non-Voting Convertible Preferred Stock | −9,413 | 0 | ||
| 2021-09-23 | Frazier Life Sciences Public Fund, L.P. 10% owner | Purchase | +200,000 | $11.00 | $2.2M | 1,505,200 |
| 2021-09-21 | Fairmount Funds Management LLC Director | Purchase | +909,000 | $11.00 | $10.0M | 938,233 |
| 2021-07-26 | Humer Kristian CFO and CBO | Grant or award · Stock Option (Right to Buy) | +360,000 | 360,000 | ||
| 2021-07-14 | Moses Jennifer K. Director | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2021-06-03 | Kiselak Tomas Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2021-06-03 | Morris Arlene Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2021-06-03 | Harwin Peter Evan Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 |
Page 9 of 10 · 182 trades